Academic audit
Betting Against Beta Factor in Stocks
The betting-against-beta effect argues that low-beta stocks earn higher risk-adjusted returns than high-beta stocks, so the factor goes long low-beta names and short high-beta names to isolate that spread.
What we found
Built naively as a decile long/short (long low-beta, short high-beta), the factor failed our test. Its placebo percentile was 0, meaning it showed no rank skill above randomly formed baskets, and its worst-year risk factor was deeply negative. The reason is structural: this construction is net short market beta, so it gives up the equity premium in every bull year and bleeds over the window. In this simple, unhedged form the famous factor is not investable.
- Survivorship-free 1077-name US common-stock panel, 2005-2026. Realistic modelled costs.
- Placebo / robustness test: real result vs random baskets or shuffled signals (real vs the 95th percentile of random)
Read the paper ↗
Research, not investment advice. “Validated” factor-legs are market-neutral diversifying building blocks with a losing worst year — none is a standalone tradeable strategy. Metrics are cost-aware and modelled (not live fills); the 2005–2026 test window is out-of-sample versus the source paper. Dollar figures are not returns and are omitted by design.